DE69716896T2 - Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression - Google Patents

Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression

Info

Publication number
DE69716896T2
DE69716896T2 DE69716896T DE69716896T DE69716896T2 DE 69716896 T2 DE69716896 T2 DE 69716896T2 DE 69716896 T DE69716896 T DE 69716896T DE 69716896 T DE69716896 T DE 69716896T DE 69716896 T2 DE69716896 T2 DE 69716896T2
Authority
DE
Germany
Prior art keywords
treating depression
substituted benzylamine
benzylamine derivatives
derivatives
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716896T
Other languages
English (en)
Other versions
DE69716896D1 (de
Inventor
Casimir Leysen
Stephanus Ruigt
Theodorus Linders
Antonius Dijcks
Simon James Anthony Grove
Duncan Robertson Rae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69716896D1 publication Critical patent/DE69716896D1/de
Publication of DE69716896T2 publication Critical patent/DE69716896T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DE69716896T 1996-04-19 1997-04-15 Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression Expired - Lifetime DE69716896T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201065 1996-04-19
PCT/EP1997/001904 WO1997040027A1 (en) 1996-04-19 1997-04-15 Substituted benzylamines and their use for the treatment of depression

Publications (2)

Publication Number Publication Date
DE69716896D1 DE69716896D1 (de) 2002-12-12
DE69716896T2 true DE69716896T2 (de) 2003-07-24

Family

ID=8223896

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716896T Expired - Lifetime DE69716896T2 (de) 1996-04-19 1997-04-15 Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression

Country Status (25)

Country Link
EP (1) EP0898566B1 (de)
JP (1) JP4008033B2 (de)
CN (1) CN1139580C (de)
AR (1) AR006719A1 (de)
AT (1) ATE227278T1 (de)
AU (1) AU725847B2 (de)
BR (1) BR9708790A (de)
CA (1) CA2251820C (de)
CZ (1) CZ295747B6 (de)
DE (1) DE69716896T2 (de)
DK (1) DK0898566T3 (de)
ES (1) ES2186888T3 (de)
HK (1) HK1018271A1 (de)
HU (1) HU224637B1 (de)
ID (1) ID17723A (de)
IL (1) IL120669A (de)
NO (1) NO311976B1 (de)
NZ (1) NZ332334A (de)
PL (1) PL192561B1 (de)
PT (1) PT898566E (de)
RU (1) RU2179553C2 (de)
TR (1) TR199802104T2 (de)
TW (1) TW498070B (de)
WO (1) WO1997040027A1 (de)
ZA (1) ZA973209B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080773A (en) 1997-10-14 2000-06-27 Akzo Nobel, N.V. Benzylamine derivatives which are useful in treating psychiatric disorders
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US7091199B1 (en) 1999-09-14 2006-08-15 Aventis Pharmaceuticals Inc. Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
US7253165B2 (en) 1999-09-14 2007-08-07 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
AU7479400A (en) * 1999-09-14 2001-04-17 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists
US7125903B1 (en) 1999-09-14 2006-10-24 Aventis Pharmaceuticals Inc. Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EP1925305A1 (de) * 2006-10-23 2008-05-28 N.V. Organon Ih-Kanal-Hemmer zur Förderung der Wachsamkeit
MX2011006680A (es) * 2008-12-24 2011-07-12 Astrazeneca Ab Compuestos etanaminicos y su uso para tratar la depresion.
EP2473489B1 (de) 2009-07-07 2013-08-21 Merck Sharp & Dohme B.V. 2-(1,2-benzisoxazol-3-yl)benzylamin-derivate
CN102942464B (zh) * 2012-12-06 2015-04-08 西北师范大学 化合物1-(2-卤苯基)-3-甲基-丁酮-1的合成方法
CN112300061B (zh) * 2020-10-06 2022-02-18 大连理工大学 一种含氮杂环二芳酮化合物的制备方法
GB202103012D0 (en) 2021-03-03 2021-04-14 King S College London Compounds
GB202103017D0 (en) 2021-03-03 2021-04-14 King S College London Compounds
GB202103008D0 (en) 2021-03-03 2021-04-14 King S College London Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
JP4008033B2 (ja) 2007-11-14
TR199802104T2 (xx) 2000-09-21
HUP9901434A3 (en) 2001-11-28
CZ334998A3 (cs) 1999-06-16
CA2251820A1 (en) 1997-10-30
PL192561B1 (pl) 2006-11-30
ZA973209B (en) 1997-11-20
EP0898566A1 (de) 1999-03-03
CZ295747B6 (cs) 2005-10-12
IL120669A0 (en) 1997-08-14
ES2186888T3 (es) 2003-05-16
NO984836L (no) 1998-12-16
JP2000508672A (ja) 2000-07-11
WO1997040027A1 (en) 1997-10-30
ATE227278T1 (de) 2002-11-15
RU2179553C2 (ru) 2002-02-20
CA2251820C (en) 2007-03-27
NZ332334A (en) 2000-06-23
HU224637B1 (hu) 2005-12-28
EP0898566B1 (de) 2002-11-06
DE69716896D1 (de) 2002-12-12
CN1219169A (zh) 1999-06-09
TW498070B (en) 2002-08-11
AU725847B2 (en) 2000-10-19
HK1018271A1 (en) 1999-12-17
HUP9901434A2 (hu) 1999-08-30
AU2387097A (en) 1997-11-12
PL329348A1 (en) 1999-03-29
AR006719A1 (es) 1999-09-08
NO311976B1 (no) 2002-02-25
CN1139580C (zh) 2004-02-25
IL120669A (en) 2001-04-30
DK0898566T3 (da) 2003-03-03
NO984836D0 (no) 1998-10-16
ID17723A (id) 1998-01-22
PT898566E (pt) 2003-03-31
BR9708790A (pt) 1999-08-03

Similar Documents

Publication Publication Date Title
DE69720463D1 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE69711067T2 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69704877T2 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE222910T1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69721756D1 (de) Paroxetine zur behandlung von depression
DE69720600D1 (de) Mittel zur Verhinderung von schlechten Gerüchen
DE69615714T2 (de) Phosphat-zusammensetzung und ihre verwendung
DE69708629T2 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
DE69717846T2 (de) Behandlungsverfahren von laktamen
DE69701458T2 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
DE69812599D1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
DE69826460D1 (de) Verwendung von niedermolekularen heparinen zur vorbeugung und behandlung von einem trauma des zentralnervensystems
DE69936496D1 (de) Verfahren zur Verfolgung und Nachführung von Waren
DE69706195T2 (de) Antikonvulsive derivate zur behandlung von psoriasis
DE69602015D1 (de) Verfahren zur coproduktion von difluormethan und 1,1,1,2-tetrafluorethan
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

R082 Change of representative

Ref document number: 898566

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE